First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).-Reference-Cited by-同舟云学术

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

Published:2014-05-20 Issue:15_suppl Volume:32 Page:LBA4-LBA4
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Piccart-Gebhart Martine J.¹,Holmes Andrew Peter²,Baselga Jose³,De Azambuja Evandro⁴,Dueck Amylou C.⁵,Viale Giuseppe⁶,Zujewski Jo Anne⁷,Goldhirsch Aron⁸,Santillana Sergio⁹,Pritchard Kathleen I.¹⁰,Wolff Antonio C.¹¹,Jackisch Christian¹²,Lang Istvan¹³,Untch Michael¹⁴,Smith Ian E.¹⁵,Boyle Frances¹⁶,Xu Binghe¹⁷,Gomez Henry Leonidas¹⁸,Gelber Richard D.¹⁹,Perez Edith A.²⁰

Affiliation:

1. Jules Bordet Institute, Breast International Group, Brussels, Belgium

2. Frontier Science Scotland Ltd, Kincraig, United Kingdom

3. Memorial Sloan Kettering Cancer Center, New York, NY

4. Institut Jules Bordet, Brussels, Université Libre de Bruxelles, Brussels, Belgium

5. Mayo Clinic, Scottsdale, AZ

6. Division of Pathology, European Institute of Oncology, Milan, Italy

7. National Cancer Institute, Bethesda, MD

8. Division of Medical Oncology, European Institute of Oncology, Milan, Italy

9. GlaxoSmithKline, Malvern, PA

10. Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, ON, Canada

11. The Johns Hopkins Hospital and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

12. Sana Kliniken Offenbach, Offenbach, Germany

13. Országos Onkológiai Intézet, Budapest, Hungary

14. Helios Klinikum Berlin-Buch, Berlin, Germany

15. The Royal Marsden NHS Foundation Trust, London, United Kingdom

16. Patricia Ritchie Centre for Cancer Care and Research, The University of Sydney, Mater Hospital, Sydney, Australia

17. Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

18. Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru

19. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

20. Mayo Clinic, Jacksonville, FL

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.lba4

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial;eBioMedicine;2022-11

2. Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World;Frontiers in Oncology;2021-07-28

3. Microbial-Based Cancer Therapy: Diagnostic Tools and Therapeutic Strategies;Microorganisms for Sustainability;2019

4. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer;Expert Review of Clinical Pharmacology;2018-12-04

5. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer;Investigational New Drugs;2018-07-30